udifitimod

Udifitimod (BMS-986166) is an orally administered small molecule prodrug developed by Bristol Myers Squibb for the treatment of autoimmune diseases, including atopic dermatitis and ulcerative colitis. After administration, it is phosphorylated in vivo to its active metabolite, BMS‑986166‑P. This metabolite acts as a selective partial agonist of the sphingosine 1-phosphate receptor 1 (S1P1R), modulating lymphocyte egress from lymphoid organs and thereby exerting immunomodulatory effects. Compared to other S1P1R modulators like fingolimod, udifitimod demonstrates a differentiated pharmacological profile with reduced cardiovascular and pulmonary side effects while maintaining efficacy in preclinical models of multiple sclerosis, inflammatory bowel disease, and systemic lupus erythematosus[1][2][4][5].

Other names

udifitimodUdifitimod [USAN]UNII-283FTA936DUNII283FTA936DUNII 283FTA936D